# Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

> **NCT00651456** · PHASE2,PHASE3 · COMPLETED · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 448 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** Standard Chemotherapy (Pemetrexed and Cisplatin)
- **DRUG:** Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab

## Key facts

- **NCT ID:** NCT00651456
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2015-01
- **Final completion:** 2016-09
- **Target enrollment:** 448 (ACTUAL)
- **Last updated:** 2023-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651456, "Mesothelioma Avastin Plus Pemetrexed-cisplatin Study". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00651456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*